IRIS
SALVATORELLI, EMANUELA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 4.387
NA - Nord America 1.754
EU - Europa 649
SA - Sud America 197
Continente sconosciuto - Info sul continente non disponibili 81
AF - Africa 29
OC - Oceania 12
Totale 7.109
Salva come PNG Salva come JPEG
Nazione #
SG - Singapore 3.155
US - Stati Uniti d'America 1.661
CN - Cina 600
HK - Hong Kong 360
IT - Italia 260
BR - Brasile 120
GB - Regno Unito 98
DE - Germania 78
FR - Francia 78
VN - Vietnam 64
BD - Bangladesh 54
CA - Canada 37
CZ - Repubblica Ceca 34
IN - India 30
MX - Messico 28
CO - Colombia 21
AR - Argentina 20
ID - Indonesia 18
NL - Olanda 18
FI - Finlandia 17
PH - Filippine 15
AU - Australia 11
EC - Ecuador 11
JP - Giappone 10
SA - Arabia Saudita 10
UA - Ucraina 10
ZA - Sudafrica 10
MY - Malesia 9
PK - Pakistan 9
JM - Giamaica 8
PL - Polonia 8
TR - Turchia 8
ES - Italia 7
PY - Paraguay 7
VE - Venezuela 7
BE - Belgio 6
CL - Cile 6
JO - Giordania 6
TW - Taiwan 6
AE - Emirati Arabi Uniti 5
CR - Costa Rica 5
NP - Nepal 5
PT - Portogallo 5
RU - Federazione Russa 5
IQ - Iraq 4
AL - Albania 3
DO - Repubblica Dominicana 3
GE - Georgia 3
IE - Irlanda 3
LT - Lituania 3
MD - Moldavia 3
PE - Perù 3
SE - Svezia 3
UZ - Uzbekistan 3
AO - Angola 2
AT - Austria 2
BO - Bolivia 2
CI - Costa d'Avorio 2
EE - Estonia 2
EG - Egitto 2
GT - Guatemala 2
HN - Honduras 2
IL - Israele 2
MA - Marocco 2
MM - Myanmar 2
NI - Nicaragua 2
SN - Senegal 2
SV - El Salvador 2
TN - Tunisia 2
BG - Bulgaria 1
BH - Bahrain 1
BN - Brunei Darussalam 1
BY - Bielorussia 1
CV - Capo Verde 1
DK - Danimarca 1
DM - Dominica 1
ET - Etiopia 1
GA - Gabon 1
KH - Cambogia 1
KN - Saint Kitts e Nevis 1
KZ - Kazakistan 1
LB - Libano 1
LK - Sri Lanka 1
LV - Lettonia 1
ME - Montenegro 1
MR - Mauritania 1
NG - Nigeria 1
NZ - Nuova Zelanda 1
OM - Oman 1
PA - Panama 1
RO - Romania 1
RW - Ruanda 1
SO - Somalia 1
SY - Repubblica araba siriana 1
TT - Trinidad e Tobago 1
XK - ???statistics.table.value.countryCode.XK??? 1
YE - Yemen 1
Totale 7.029
Salva come PNG Salva come JPEG
Città #
San Jose 491
Hong Kong 358
Singapore 343
Ashburn 266
Rome 198
Beijing 178
Hefei 162
Council Bluffs 111
Boardman 93
Columbus 83
London 73
Dallas 65
Lauterbourg 65
Santa Clara 55
Shanghai 53
Munich 38
Los Angeles 33
New York 24
Brno 23
San Francisco 23
Ho Chi Minh City 22
Redmond 21
Hanoi 16
Mexico City 16
São Paulo 16
Amsterdam 15
Pune 15
Phoenix 14
Guangzhou 12
Seattle 12
Olomouc 10
Toronto 10
Turku 10
Washington 10
Manchester 9
Tokyo 9
Bogotá 8
Boston 8
Brooklyn 8
Chicago 8
Haiphong 8
Buffalo 7
Nuremberg 7
Rio de Janeiro 7
Hangzhou 6
Helsinki 6
Warsaw 6
Amman 5
Atlanta 5
Campinas 5
Frankfurt am Main 5
Kuala Lumpur 5
Melbourne 5
Orem 5
Palermo 5
Riyadh 5
San José 5
The Dalles 5
Biên Hòa 4
Caracas 4
Chennai 4
Dhaka 4
Guayaquil 4
Johannesburg 4
Las Vegas 4
Manila 4
Medellín 4
Milan 4
Paris 4
Piscataway 4
Shenzhen 4
Taipei 4
Wuhan 4
Ankara 3
Brasília 3
Buenos Aires 3
Canberra 3
Columbia 3
Dublin 3
Genoa 3
Haikou 3
Karachi 3
Kingston 3
Lancaster 3
Mol 3
Montreal 3
New Delhi 3
Philadelphia 3
Quito 3
Québec 3
Stockholm 3
Sydney 3
Tashkent 3
Tbilisi 3
Tirana 3
Xiamen 3
Alexandria 2
Asunción 2
Augusta 2
Aversa 2
Totale 3.223
Salva come PNG Salva come JPEG
Nome #
Pharmacology of Ranolazine versus Common Cardiovascular Drugs in Patients with Early Diastolic Dysfunction Induced by Anthracyclines or Nonanthracycline Chemotherapeutics: A Phase 2b Minitrial 238
Cardiovascular safety of anti-TNF-alpha therapies: Facts and unsettled issues. 232
Doxorubicinolone formation and efflux : A salvage pathway against epirubicin accumulation in human heart 210
Anthracyclines and Cardiotoxicity: Is CARP a Forgotten Biomarker? 209
Cancer drugs and QT prolongation: weighing risk against benefit 208
Choosing Antifungals for the Midostaurin-Treated Patient: Does CYP3A4 Outweigh Recommendations? A Brief Insight from Real Life 208
Minimal sampling colistin pharmacokinetics in critically ill patients 204
The endogenous lusitropic and chronotropic agent, B-type natriuretic peptide, limits cardiac troponin release in cancer patients with an early impairment of myocardial relaxation induced by anthracyclines 199
Cardiovascular toxicity of antitumor drugs :Translating molecular mechanisms into clinical facts 199
4’- Epidoxorubicin to reexplore anthracycline degradation in cardiomyocytes 198
Beyond hypertension: Diastolic dysfunction associated with cancer treatment in the era of cardio-oncology 186
Anthracycline cardiotoxicity in breast cancer patients: Synergism with trastuzumab and taxanes 186
Defective taxane stimulation of epirubicinol formation in the human heart: Insights into the cardiac tolerability of epirubicin-taxane chemotherapies 181
Chronic cardiotoxicity of anticancer anthracyclines in the rat: role of secondary metabolites and reduced toxicity by a novel anthracycline with impaired metabolite formation and reactivity 163
Anthracycline Cardiotoxicity 146
Pharmacology of cardio-oncology: chronotropic and lusitropic effects of B-type natriuretic peptide in cancer patients with early diastolic dysfunction induced by anthracycline or nonanthracycline chemotherapy 140
Anthracyclines 131
Anthracycline degradation in cardiomyocytes: a journey to oxidative survival 130
Anthracycline Cardiotoxicity 116
Defective one or two electron reduction of the anticancer anthracycline epirubicin in human heart: Relative importance of vesicular sequestration and impaired efficiency of electron addition 108
Cardiotoxicity of antitumor drugs 104
CARDIAC ANTHRACYCLINE ACCUMULATION AND B-TYPE NATRIURETIC PEPTIDE TO DEFINE RISK AND PREDICTORS OF CANCER TREATMENT RELATED EARLY DIASTOLIC DYSFUNCTION 102
Advances in Bruton tyrosine kinase (Btk) inhibition are steered by Bruton tyrosine kinase phylogeny 98
Cardiotoxicity of targeted cancer drugs: concerns, “The cart before the horse,” and lessons from trastuzumab 95
Low dose anthracycline and risk of heart failure in a pharmacokinetic model of human myocardium exposure: analog specificity and role of secondary alcohol metabolites 94
Anthracyclines: molecular advances and pharmacological developments in antitumor activity and cardiotoxicity 92
Anthracyclines, diastolic dysfunction and the road to heart failure in Cancer survivors: An untold story 80
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model II. Amrubicin shows metabolic advantages over doxorubicin and epirubicin 75
Isavuconazole: case report and pharmacokinetic considerations 74
Telaprevir raises the plasma/whole blood ribavirin ratio: trying to come full circle on a dangerous relationship 71
Rethinking drugs from chemistry to therapeutic opportunities: Pixantrone beyond Anthracyclines. 71
Modeling human myocardium exposure to doxorubicin defines the risk of heart failure from low-dose doxorubicin 70
Low level tumor necrosis factor-alpha protects cardiomyocytes against high level tumor necrosis factor-alpha: brief insight into a beneficial paradox 69
Pharmacology of Cardio-Oncology 68
What is cardiotoxicity? 65
From Cardiac Anthracycline Accumulation to Real-Life Risk for Early Diastolic Dysfunction: A Translational Approach 64
Further analytical, pharmacokinetic, and clinical observations on low-dose ponatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia 64
In vitro modelling of the structure-activity determinants of anthracycline cardiotoxicity. 64
Paclitaxel and docetaxel stimulation of doxorubicinol formation in the human heart: Implications for cardiotoxicity of doxorubicin-taxane chemotherapies 63
Doxorubicin-Dependent Reduction of Ferrylmyoglobin and Inhibition of Lipid Peroxidation: Implications for Cardiotoxicity of Anticancer Anthracyclines 63
NEW TARGETED DRUGS FOR ACUTE MYELOID LEUKEMIA AND ANTIFUNGALS: PHARMACOKINETIC CHALLENGES AND OPPORTUNITIES 62
Pharmacokinetics of pegylated liposomal doxorubicin administered by intraoperative hyperthermic intraperitoneal chemotherapy to patients with advanced ovarian cancer and peritoneal carcinomatosis 62
Predictors of early or delayed diastolic dysfunction after anthracycline-based or nonanthracycline chemotherapy: a pharmacological appraisal 61
Ponatinib induces a persistent molecular response and graft-versus-host disease/graft-versus-leukemia effect in a patient with Philadelphia-positive acute lymphoblastic leukemia with a T315I mutation following early relapse after allogeneic transplant 60
Posaconazole and midostaurin in patients with FLT3-mutated acute myeloid leukemia: Pharmacokinetic interactions and clinical facts in a real life study 59
The novel anthracenedione, pixantrone, lacks redox activity and inhibits doxorubicinol formation in human myocardium: Insight to explain the cardiac safety of pixantrone in doxorubicin treated patients 59
Pharmacological Foundation of Cardio-Oncology 57
Doxorubicin irreversibly inactivates Iron Regulatory Proteins 1 and 2 in cardiomyocytes : Evidence for distinct metabolic pathways and implications for iron-mediated cardiotoxicity of antitumor therapy 57
Mechanisms and clinical course of cardiovascular toxicity of cancer treatment II. Hematology 56
Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin 56
Modified colistin regimen for critically ill patients with acute renal impairment and continuous renal replacement therapy 55
Oxidative degradation of cardiotoxic anticancer anthracyclines to phthalic acids. Novel function or ferrylmyoglobin 55
The concomitant management of cancer therapy and cardiac therapy 54
Doxorubicin metabolism to toxic species in human myocardium: stimulation by paclitaxel and docetaxel but not BMS 184476 or BMS 188797 53
Formation of toxic anthracycline secondary alcohol metabolites in human myocardium: Comparisons between doxorubicin and epirubicin and effects of paclitaxel, docetaxel, and the epothilones BMS310705 and BMS247550 49
Matters of the heart: The case of TNF-alpha targeting drugs 48
Doxorubicin degradation in cardiomyocytes 47
The novel anthracycline MEN 10755 is less cardiotoxic than doxorubicin or epirubicin due to reduced formation and aconitase-reactivity its secondary alcohol metabolite 47
Pharmacokinetic characterization of amrubicin cardiac safety in an ex vivo human myocardial strip model I Amrubicin accumulates to a lower level than doxorubicin or epirubicin 46
Impairment of myocardial contractility by anticancer anthracyclines: role of secondary alcohol metabolites and evidence of reduced toxicity by a novel disaccharide analogue 46
Tumour necrosis factor alpha (TNFα)cardiomyocyte preconditioning: clues to explain anti-TNFα agents contraindication in severe heart failure 46
Managing anthracycline-induced cardiotoxicity: beginning with the end in mind 46
Primary prevention strategies for anthracycline cardiotoxicity: a brief overview 45
Role of secondary alcohol metabolites in anthracycline cardiotoxicity: from hypotheses to new drugs 45
The use of pegylated liposomal doxorubicin with hyperthermic intraperitoneal chemotherapy (HIPEC) in patients undergoing cytoreductive surgery (CS) for peritoneal carcinomatosis of ovarian origin 45
Molecular determinants of the reduced cardiotoxicity of epirubicin 45
Doxorubicin dependent reduction of hypervalent ferrylmyoglobin: One more evidence against the oxidative nature of doxorubicin-induced cardiotoxicity 45
The reality of pixantrone in real life 44
Tumor necrosis factor alpha and cardiomyocytes: evidence for a self-protective preconditioning 42
Doxorubicin inhibits ferrylmyoglobin-dependent lipid peroxidation 42
Taxanes stimolate Doxorubicin conversion to its cardiotoxic secondary alcohol metabolite doxorubicinol: studies in human myocardium 42
Ferrylmyoglobin-dependent oxidative degradation of doxorubicin: a novel pathway of anthracycline metabolism and toxicity 42
Tnf-alpha induced cardioprotection: effects on reactive oxygen species (ros) and apoptosis 42
Efficacy and safety of low dose ponatinib in a case of Ph-positive acute lymphoblastic leukaemia 40
Translating molecular mechanisms into clinical facts 40
Taxanes stimulate doxorubicin conversion to its cardiotoxic secondary alcohol metabolite : Studies in human myocardium. 38
Humans and Rodents: The Case of hOAT4 and mOat5 37
Do you know pixantrone? 37
Doxorubicin Cardiotoxicity and the Control of Iron Metabolism: Quinone-Dependent and Independent Mechanisms 37
Increasing doxorubicin antitumor activity through COX-2 inhibition without increasing cardiotoxicity 37
Pixantrone (PIX) Inhibition of Doxorubicinol (DOXOL) Formation in Human Myocardium: Implications for Cardiac Safety in Non-Hodgkin Lymphoma (NHL) Patients with Prior Anthracycline Treatment 36
Adjudication of Adverse Cardiovascular Events in Patients with Chronic Lymphocytic Leukaemia Treated with Ibrutinib: Deaths in GLOW or Blowing in the Wind? 9
Totale 7.109
Salva come PNG Salva come JPEG
Categoria #
all - tutte 45.675
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.675
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022182 0 0 0 0 0 0 1 73 3 0 4 101
2022/202346 1 1 1 3 2 2 10 0 2 3 20 1
2023/2024280 5 32 8 12 32 123 4 16 2 7 4 35
2024/20253.593 74 34 107 13 42 68 37 20 222 238 1.303 1.435
2025/20262.570 294 186 127 209 108 62 793 174 182 231 99 105
2026/2027434 69 283 82 0 0 0 0 0 0 0 0 0
Totale 7.109